[{"data":1,"prerenderedAt":221},["ShallowReactive",2],{"$ftp8cn90i7gnw":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":54,"top_diseases":80,"top_companies":112,"key_results":142,"trends":207,"previous_editions":216,"comparison":147,"highlighted_classes":217},1,"ddw-2026","DDW","ddw","Digestive Disease Week 2026",2026,"Gastroenterology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},5104,1218,221,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":18,"Phase 3":21},12,4,26,3,64,[23,27,31,35,38,40,43,45,47,50],{"name":24,"count":25,"share":26},"GLP1R",89,7,{"name":28,"count":29,"share":30},"IL23A",68,6,{"name":32,"count":33,"share":34},"TNFA",55,5,{"name":36,"count":37,"share":18},"GR",49,{"name":39,"count":37,"share":18},"α4β7",{"name":41,"count":42,"share":18},"ITGA4",47,{"name":44,"count":42,"share":18},"ITGB7",{"name":46,"count":42,"share":18},"JAK1",{"name":48,"count":49,"share":20},"ATP4A",40,{"name":51,"count":52,"share":53},"IL12B",30,2,[55,59,63,66,69,72,75,78],{"name":56,"count":57,"share":58},"Small molecules",750,62,{"name":60,"count":61,"share":62},"Monoclonal antibodies",295,24,{"name":64,"count":65,"share":17},"Peptides",142,{"name":67,"count":68,"share":26},"Carbohydrate, lipid and polymer therapeutics",88,{"name":70,"count":71,"share":34},"Non-antibody therapeutic proteins",65,{"name":73,"count":74,"share":34},"Microbial and phage therapeutics",57,{"name":76,"count":77,"share":20},"Bispecific antibodies",39,{"name":79,"count":77,"share":20},"Natural-product mixtures and botanicals",[81,85,89,93,96,98,101,104,107,109],{"name":82,"count":83,"share":84},"autoimmune colitis",243,20,{"name":86,"count":87,"share":88},"Crohn's disease",210,17,{"name":90,"count":91,"share":92},"inflammatory bowel disease (IBD)",176,14,{"name":94,"count":95,"share":30},"obesity",77,{"name":97,"count":33,"share":34},"Cirrhosis",{"name":99,"count":100,"share":18},"colorectal cancer (CRC)",46,{"name":102,"count":103,"share":18},"Colitis",45,{"name":105,"count":106,"share":18},"type 2 diabetes mellitus (T2DM)",44,{"name":108,"count":49,"share":20},"metabolic dysfunction-associated steatotic liver disease (MASLD)",{"name":110,"count":111,"share":20},"eosinophilic esophagitis (EoE)",38,[113,117,119,122,125,128,130,133,136,139],{"name":114,"count":115,"share":116},"Johnson & Johnson",101,8,{"name":118,"count":68,"share":26},"Takeda",{"name":120,"count":121,"share":30},"AbbVie",69,{"name":123,"count":124,"share":30},"Novo Nordisk",67,{"name":126,"count":127,"share":34},"Pfizer",63,{"name":129,"count":42,"share":18},"Eli Lilly",{"name":131,"count":132,"share":20},"Merck",37,{"name":134,"count":135,"share":20},"Bristol Myers Squibb",35,{"name":137,"count":138,"share":53},"Bayer",28,{"name":140,"count":141,"share":53},"GSK",23,[143,151,157,163,169,177,184,192,199],{"title":144,"drug":145,"company":147,"phase":148,"disease":82,"finding":149,"url":150},"Improvements in patient-reported fatigue among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod: pooled results from the 8-WEEK ABTECT-1 and ABTECT-2 phase 3 double-blind, placebo-controlled induction trials",{"name":146,"slug":146},"obefazimod",null,"Phase 3","At Week 8, a greater proportion of Obe patients had a remission of FACIT-F: 22.2% for Obe-50 and 28.3% for Obe-25 vs 13.4% for PBO (Obe-50:Δ9.0, p\u003C0.05 and Obe-25:Δ14.6, p=0.001).","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4195711\u002Fmarla.dubinsky.improvements.in.patient-reported.fatigue.among.patients.with.html",{"title":152,"drug":153,"company":147,"phase":148,"disease":82,"finding":155,"url":156},"Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active ulcerative colitis: post-hoc analysis of QUASAR",{"name":154,"slug":154},"guselkumab","With SC induction (ASTRO), 35.8% of SC GUS vs 25.9% of PBO pts were in symptomatic response at W2; 12.2% vs 7.9%, respectively, were in symptomatic remission.","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4195552\u002Ftadakazu.hisamatsu.symptomatic.improvement.with.intravenous.guselkumab.html",{"title":158,"drug":159,"company":147,"phase":148,"disease":86,"finding":161,"url":162},"Mirikizumab is efficacious in moderately to severely active Crohn’s Disease after one prior anti-TNF failure",{"name":160,"slug":160},"mirikizumab","At W52, a statistically significantly higher proportion of mirikizumab-treated participants achieved CDAI remission–composite (mirikizumab: 44.0%; placebo: 15.5%; P\u003C0.001) and endoscopic response–composite (mirikizumab: 37.1%; placebo: 6.9%; P\u003C0.001) compared with placebo.","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4195563\u002Fchristopher.ma.mirikizumab.is.efficacious.in.moderately.to.severely.active.html",{"title":164,"drug":165,"company":147,"phase":148,"disease":110,"finding":167,"url":168},"Combined histologic, endoscopic, and symptomatic remission in adults and adolescents with eosinophilic esophagitis through dupilumab treatment: A post-hoc analysis of the phase 3 LIBERTY EoE TREET study",{"name":166,"slug":166},"dupilumab","The proportion of patients achieving combined histologic–endoscopic-symptomatic remission with dupilumab vs placebo was 21.3% vs 1.7% at W24, with all patients in Part C receiving dupilumab; the proportions at W52 were 24.6% (dupilumab–dupilumab) and 21.6% (placebo–dupilumab).","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4198886\u002Fevan.dellon.combined.histologic.endoscopic.and.symptomatic.remission.in.adults.html",{"title":170,"drug":171,"company":147,"phase":173,"disease":174,"finding":175,"url":176},"Efficacy and safety of brivekimig (a dual-target, anti-tumour necrosis factor and anti-OX40 ligand NANOBODY®) in participants with moderate-to-severe hidradenitis suppurativa: implications for inflammatory bowel diseases",{"name":172,"slug":172},"brivekimig","Phase 2","hidradenitis suppurativa (HS)","W16 HiSCR50 median response rates were 67% (brivekimig, N=48) and 37% (placebo, N=23).","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4196881\u002Fjean.frederic.colombel.efficacy.and.safety.of.brivekimig.28a.dual-target.html",{"title":178,"drug":179,"company":147,"phase":173,"disease":82,"finding":182,"url":183},"Safety, tolerability, and efficacy of PL8177 in adults with active ulcerative colitis: results from a phase 2A, randomized, placebo-controlled study",{"name":180,"slug":181},"PL8177","pl8177","Clinical remission was achieved by 3 of 9 participants (33%) in the PL8177 group (vs none with placebo), while symptomatic remission was achieved by 5 of 9 (56%) with PL8177 (vs 1 of 3 [33%] with placebo).","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4195560\u002Fdana.lukin.safety.tolerability.and.efficacy.of.pl8177.in.adults.with.active.html",{"title":185,"drug":186,"company":147,"phase":173,"disease":189,"finding":190,"url":191},"A randomised double-blind placebo-controlled phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal microbiota product in patients with irritable bowel syndrome with constipation and diarrhoea; the TrIuMPH trial",{"name":187,"slug":188},"EBX-102-02","ebx-102-02","Diarrhea-predominant irritable bowel syndrome (IBS-D)","At Week 7, mean (SE) IBS-SSS reduction was 61 (15) points with EBX-102-02 compared with 38 (17) points for placebo.","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4197016\u002Fjames.mcilroy.a.randomised.double-blind.placebo-controlled.phase.ii.trial.html",{"title":193,"drug":194,"company":147,"phase":173,"disease":196,"finding":197,"url":198},"Volixibat leads to improvements in fatigue and sleep for adults with primary biliary cholangitis: data from VANTAGE",{"name":195,"slug":195},"volixibat","primary biliary cholangitis (PBC)","A higher proportion of VLX-treated participants reported normal\u002Fmild fatigue and sleep disturbances after 28 weeks of treatment compared to BL (Fatigue: BL: 8\u002F14, W 28: 10\u002F14; Sleep: BL: 10\u002F14, W28: 13\u002F14), with minimal changes in PBO-treated participants.","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4199800\u002Fmitchell.shiffman.volixibat.leads.to.improvements.in.fatigue.and.sleep.for.html",{"title":200,"drug":201,"company":147,"phase":204,"disease":90,"finding":205,"url":206},"ISM5411, a novel gut-restricted PHD1\u002F2 inhibitor for inflammatory bowel disease: a randomized, double-blind, placebo-controlled, first-in-human Phase I study to evaluate safety, tolerability and PK profiles",{"name":202,"slug":202,"named_as":203},"garutadustat","ISM5411","Phase 1","The incidence of TEAEs was 25.0% and 55.0% in the ISM5411 pooled cohort (n=56) and placebo cohort (n=20), respectively.","https:\u002F\u002Feposters.ddw.org\u002Fddw\u002F2026\u002Fddw-2026\u002F4195570\u002Fcarol.satler.ism5411.a.novel.gut-restricted.phd1.2.inhibitor.for.inflammatory.html",{"summary":208,"bullets":210},[209],"Small molecules were the most frequent modality (62% of drug-linked abstracts). GLP1R was the most frequent target (7%). Autoimmune colitis was the most frequent disease (20%).",[211,212,213,214,215],"Johnson & Johnson had the largest company share (8% of drug-linked abstracts).","Bispecific antibodies accounted for 3% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (24%).","IL23A was the next most frequent target (6%).","Crohn's disease was the next most frequent disease (17%).",[],[218,219],{"name":76,"count":77,"share":20,"previous_count":147,"previous_share":147,"direction":147},{"name":220,"count":25,"share":26,"previous_count":147,"previous_share":147,"direction":147},"GLP-1 receptor drugs",1793970603079]